Azitra, Inc., a pre-clinical biopharmaceutical company, focuses on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It is developing ATR-12, a genetically modified strain of S. epidermidis for treating Netherton syndrome, a skin disease; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. The company was incorporated in 2014 and is based in Branford, Connecticut.
Company profile
Ticker
AZTR
Exchange
Website
CEO
Mr. Francisco D. Salva
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Azitra Inc
SEC CIK
Corporate docs
IRS number
464478536
AZTR stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
9 Oct 24
DEF 14A
Definitive proxy
9 Oct 24
8-K
Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates
12 Aug 24
10-Q
2024 Q2
Quarterly report
12 Aug 24
8-K
Azitra, Inc. Announces Pricing of
26 Jul 24
424B5
Prospectus supplement for primary offering
25 Jul 24
EFFECT
Notice of effectiveness
24 Jul 24
S-1/A
IPO registration (amended)
19 Jul 24
FWP
Free writing prospectus
15 Jul 24
S-1
IPO registration
15 Jul 24
Latest ownership filings
144
Notice of proposed sale of securities
16 Sep 24
SC 13D/A
Bios Equity Partners, LP
2 Aug 24
SC 13G
CVI Investments, Inc.
1 Aug 24
SC 13G
L1 Capital Global Opportunities Master Fund, Ltd.
29 Jul 24
4
Norm Staskey
1 Apr 24
SC 13G
LYTTON LAURENCE W
27 Feb 24
SC 13G/A
Alpha 18 Inc.
26 Feb 24
SC 13G
Alpha 18 Inc.
26 Feb 24
4
Travis Whitfill
15 Feb 24
4
Norm Staskey
15 Feb 24
Financial summary
Quarter (USD) | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | |
---|---|---|
Revenue | ||
Cost of revenue | ||
Operating income | ||
Operating margin | ||
Net income | ||
Net profit margin | ||
Cash on hand | ||
Change in cash | ||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 803.08 k | 803.08 k | 803.08 k | 803.08 k | 803.08 k | 803.08 k |
Cash burn (monthly) | 732.39 k | 457.27 k | 886.76 k | 849.63 k | (no burn) | 253.41 k |
Cash used (since last report) | 2.92 mm | 1.82 mm | 3.54 mm | 3.39 mm | n/a | 1.01 mm |
Cash remaining | -2.12 mm | -1.02 mm | -2.73 mm | -2.58 mm | n/a | -207.21 k |
Runway (months of cash) | -2.9 | -2.2 | -3.1 | -3.0 | n/a | -0.8 |
Institutional ownership, Q2 2024
90.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 1 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 46.75 mm |
Total shares | 6.90 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Bios Equity Partners | 6.80 mm | $33.32 mm |
Geode Capital Management | 101.76 k | $13.43 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Norm Staskey | Common Stock | Buy | Acquire P | No | No | 0.2108 | 47,600 | 10.03 k | 51,100 |
13 Feb 24 | Travis Whitfill | Common Stock | Buy | Acquire P | No | No | 0.3 | 15,000 | 4.50 k | 334,500 |
13 Feb 24 | Norm Staskey | Common Stock | Buy | Acquire P | No | No | 0.3 | 3,300 | 990.00 | 3,500 |
13 Feb 24 | Francisco D. Salva | Common Stock | Buy | Acquire P | No | No | 0.3 | 333,300 | 99.99 k | 338,300 |
8 Sep 23 | Norm Staskey | Stock Options Common Stock | Grant | Acquire A | No | No | 2.07 | 10,000 | 20.70 k | 10,000 |
News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
24 Oct 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
24 Oct 24
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
4 Oct 24
Azitra Announces Late-Breaking Presentation Related To ATR-04 At The EADV Congress
24 Sep 24
Azitra Receives Study May Proceed Letter From The FDA For IND To Treat Skin Rash From EGFR Inhibitors
22 Aug 24
Press releases
Azitra to Present at BIO-Europe 2024
29 Oct 24
Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit
11 Oct 24
Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference
6 Sep 24
Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome
28 Aug 24
Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome
20 Aug 24